Select Page

FOR IMMEDIATE RELEASE

June 30, 2010

PRESS CONTACT:

Christopher Davis, Kelly Kapaun

805.687.3322

Cancer Center of Santa Barbara Physicians Publish Research in Leading Science and Medicine Journals

Santa Barbara, CALocal physicians from the Cancer Center of Santa Barbara are publishing exciting new cancer research studies in leading cancer publications.

“It’s thrilling for the Cancer Center to be on the front lines of cancer research,” said Rick Scott, Cancer Center of Santa Barbara President.  “Research is a big part of our mission because it drives innovation in cancer diagnosis and treatment.  We are fortunate to have physicians who are not only outstanding clinicians, but who also participate in important research as part of the Cancer Center team.”

Summaries of published research included below.  To read full-text articles, please visit the Cancer Center’s Resource Library at 540 West Pueblo Street, or visit the cancer center’s website: www.ccsb.org/physicianresearch.

  • Dr. Daniel Greenwald and his collaborators at UCSB published an article entitled Co-administration of Tumor-Penetrating Peptide Enhances Efficacy of Cancer Drugs in a recent issue of Science. The research focused on new ways to deliver anticancer drugs into tumors. They showed that a known tumor-penetrating protein increased permeability in tumors and allowed chemotherapy drugs administered at the same time to accumulate in the tumors, while reducing potential damage to healthy tissues.
  • Dr. W. Warren Suh contributed to a recent study published in the International Journal of Radiation Oncology Biology Physics, Biological In Situ Dose Painting for IGRT with Drug-Loaded Implantable Devices. This study explored new opportunities for radiation therapy modulation using implantable devices commonly used in image-guided radiation treatments (IGRT). The purpose of the research was to study implantable devices that are routinely used in radiation therapy treatment and the potential for these devices to release biologically active drugs, providing an opportunity to make the treatment even more effective.
  • Dr. Suh also participated in a recent study which appeared in the journal Cancer examining post-radiation therapy prostate cancer patients and their individual risk of mortality from causes other than prostate cancer in order to understand which patients might benefit from hormonal therapy. The article is entitled Comorbidity, Body Mass Index, and Age, and the Risk of Nonprostate-Cancer- Specific Mortality After a Postradiation Prostate-Specific Antigen Recurrence.

  • Dr. Alan Bryce contributed to a recent study examining the effectiveness and safety of the combination of oral Topotecan and intravenous Carboplatin in patients with untreated small cell lung cancer. Phase II Trial of Oral Topotecan and Intravenous Carboplatin with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer appeared in a 2009 issue of the American Journal of Clinical Oncology.

  • Dr. Fred Kass participated in a study called Differential Response of Triple-Negative Breast Cancer to a Docetaxel and Carboplatin-Based Neoadjuvant Treatment which appeared in a June 2010 edition of Cancer. The study evaluated response to neoadjuvant treatment in patients with locally advanced breast cancer, examining the difference in response among three subtypes of breast cancer, including triple negative breast cancer, a newly recognized subtype of breast cancer with typically poor outcomes.

Since 1949, the Cancer Center of Santa Barbara has remained in the vanguard of comprehensive outpatient cancer treatment with personnel from some of the nation’s renowned medical programs, the latest science and technology, and integrative wellness and patient support programs. The independent and charitably supported Cancer Center of Santa Barbara has earned a reputation for compassionately serving those on the journey to live with, through, and beyond cancer. www.ccsb.org

Pin It on Pinterest

Share This